Note 9 - Segment Information and Disaggregated Revenue

9 Months Ended

Mar. 31, 2025

Notes to Financial Statements

Segment Reporting Disclosure [Text Block]

Note 9. Segment Information and Disaggregated Revenue

The basis for presenting segment results generally is consistent with overall Company reporting. The Company reports information about its operating segments in accordance with GAAP which establishes standards for reporting information about a company’s operating segments.

The Company has divided its operations into two reportable segments as follows: Contract Manufacturing, and Other Nutraceutical Businesses. International sales, concentrated primarily in Europe, for the three months ended March 31, 2025 and 2024 were $3,228 and $1,980, respectively and for the nine months ended March 31, 2025 and 2024 were $7,768 and $5,245, respectively.

Financial information relating to the three months ended March 31, 2025 and 2024 operations by business segment and disaggregated revenues was as follows:

		Sales, Net						Segment
		U.S.		International				Gross					Capital
		Customers		Customers		Total		Profit (loss)			Depreciation		Expenditures
Contract Manufacturing	2025	$	10,231	$	3,228	$	13,459	$	1,522		$	76	$	116
	2024		10,770		1,980		12,750		1,250			77		345
Other Nutraceutical Businesses	2025		488		-		488		29			-		-
	2024		397		-		397		(2	)		-		-
Total Company	2025		10,719		3,228		13,947		1,551			76		116
	2024		11,167		1,980		13,147		1,248			77		345

Financial information relating to the nine months ended March 31, 2025 and 2024 operations by business segment and disaggregated revenues was as follows:

		Sales, Net						Segment
		U.S.		International				Gross				Capital
		Customers		Customers		Total		Profit		Depreciation		Expenditures
Contract Manufacturing	2025	$	30,334	$	7,768	$	38,102	$	3,497	$	246	$	201
	2024		31,022		5,218		36,240		2,563		231		404
Other Nutraceutical Businesses	2025		2,076		-		2,076		596		1		-
	2024		1,304		27		1,331		37		1		3
Total Company	2025		32,410		7,768		40,178		4,093		247		201
	2024		32,326		5,245		37,571		2,600		232		407

	Total Assets as of
	March 31,		June 30,
	2025		2024
Contract Manufacturing	$	19,880	$	20,830
Other Nutraceutical Businesses		5,776		5,377
Total Company	$	25,656	$	26,207